Sequencing asymmetry: the case for caution before first-line pirtobrutinib in chronic lymphocytic leukemia.

Abstract excerpt

The phase III BRUIN CLL-313 and CLL-314 trials have established pirtobrutinib, a noncovalent Bruton tyrosine kinase (BTK) inhibitor, as a candidate for first-line therapy in chronic lymphocytic leukemia (CLL), and all-lines regulatory approval has now been granted in the European Union. We highlight an untested asymmetry: after failure of covalent BTK inhibitors, pirtobrutinib retains phase III-validated...

Topics

• Humans
• Leukemia, Lymphocytic, Chronic, B-Cell
• Pyrimidines
• Protein Kinase Inhibitors
• Drug Resistance, Neoplasm
• Agammaglobulinaemia Tyrosine Kinase